Abhijit Debnath

@nietpharmacy.co.in

Pharmaceutics
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida



                                

https://researchid.co/theabhijitdn

RESEARCH INTERESTS

Drug Discovery, Cancer, Computer Aided Drug Design, MD Simulation

9

Scopus Publications

2

Scholar Citations

1

Scholar h-index

Scopus Publications

  • In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics Simulation Study
    Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Singh, and Shikha Srivastava

    Bentham Science Publishers Ltd.
    Background: Multiple myeloma (MM) is a hematological malignancy of plasma cells that produce a monoclonal immunoglobulin protein. Despite significant advances in the treatment of MM, currently available therapies are associated with toxicity and resistance. As a result, there is an increasing demand for novel, effective therapeutics. Inhibition of histone deacetylases (HDACs) is emerging as a potential method for treating cancer. HDAC6 is one of 18 different HDAC isoforms that regulate tubulin lysine 40 and function in the microtubule network. HDAC6 participates in tumorigenesis and metastasis through protein ubiquitination, tubulin, and Hsp90. Several studies have found that inhibiting HDAC6 causes AKT and ERK dephosphorylation, which leads to decreased cell proliferation and promotes cancer cell death via the PI3K/AKT and MAPK/ERK signaling pathways. Objective: The objective of this study is to target HDAC6 and identify potent inhibitors for the treatment of multiple myeloma by employing computer-aided drug design. Materials and Methods: A total of 199,611,439 molecules from five different chemical databases, such as CHEMBL25, ChemSpace, Mcule, MolPort, and ZINC, have been screened against HDAC6 by structure- based virtual screening, followed by filtering for various drug-likeness, ADME, toxicity, consensus molecular docking, and 100 ns MD simulation. Results: Our research work resulted in three molecules that have shown strong binding affinity (CHEMBL2425964 -9.99 kcal/mol, CHEMBL2425966 -9.89 kcal/mol, and CSC067477144 -9.86 kcal/mol) at the active site HDAC6, along with effective ADME properties, low toxicity, and high stability. Inhibiting HDAC6 with these identified molecules will induce AKT and ERK dephosphorylation linked to reduced cell proliferation and promote cancer cell death. Conclusion: CHEMBL2425964, CHEMBL2425966, and CSC067477144 could be effective against multiple myeloma.




  • A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
    Rupa Mazumder, Kamal Kant Kaushik, Abhijit Debnath, and Manisha Patel

    Bentham Science Publishers Ltd.
    Background: Even with the massive increase in financial investments in pharmaceutical research over the last decade, the number of new drugs approved has plummeted. As a result, finding new uses for approved pharmaceuticals has become a prominent alternative approach for the pharmaceutical industry. Objective: Drug repurposing or repositioning is a game-changing development in the field of drug research that entails discovering additional uses for previously approved drugs. Methods: In comparison to traditional drug discovery methods, drug repositioning enhances the preclinical steps of creating innovative medications by reducing the cost and time of the process. Drug repositioning depends heavily on available drug-disease data, so the fast development of available data as well as developed computing skills has resulted in the boosting of various new drug repositioning methods. The main goal of this article is to describe these different methods and approaches for drug repurposing. Results: The article describes the basic concept of drug repurposing, its significance in discovering new medications for various disorders, drug repurposing approaches such as computational and experimental approaches, and previous as well as recent applications of drug repurposing in diseases such as cancer, COVID-19, and orphan diseases. Conclusion: The review also addresses obstacles in drug development using drug repurposing strategies, such as a lack of financing and regulatory concerns and concludes with outlining recommendations for overcoming these challenges.

  • High-throughput virtual screening of novel CHK1 inhibitors


  • A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT
    MANISHA PATEL, RUPA MAZUMDER, KAMAL KANT KAUSHIK, ABHIJIT DEBNATH, RAKHI MISHRA, and SHUBHAM PAL

    Innovare Academic Sciences Pvt Ltd
    A novel coronavirus disease, which is transmitted from human to human has quickly become the cause of the current worldwide health crisis. This virus is, also known as SARS coronavirus, belongs to the Coronaviridae family of viruses. The recent outbreak of acute respiratory disorders starting in Wuhan, China is found to be caused by this virus. The condition caused by it, known as COVID-19 has spread very rapidly all over the world, causing so many death. This led WHO on Mar 11, 2020, to designate it as a global pandemic. An update on the history, etiology, epidemiology, pathophysiology and preventive methods for COVID-19 such as masking, quarantine, and social distancing are discussed in this paper. Repurposed drugs, antibodies, corticosteroids, vaccination and plasma transfusion, are among the treatments explained in the study. Finally, the study discusses India’s COVID vaccination programme. The major aspects of this entire review are to describe COVID-19 infection, its prevention and treatment approach.

  • IN-SILICO INVESTIGATION BASED PLANT SECONDARY METABOLITES AS PROMISING IMMUNOSTIMULANTS AGAINST COVID-19



RECENT SCHOLAR PUBLICATIONS

  • In Silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (5), 961-978 2024

  • In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening.
    A Debnath, S Sharma, R Mazumder, A Mazumder, R Kumar, A Kumar, ...
    Current Drug Discovery Technologies 2023

  • Potential of Azadirachta indica A. Juss., Eucalyptus globulus Labill. and Ocimum sanctum L. Phytochemicals as Herbal Hand Sanitizer: A Review.
    P Jain, R Mishra, A Debnath, S Sharma
    Allelopathy Journal 60 (2) 2023

  • Quest for Discovering Novel CDK12 Inhibitor by Leveraging High-Throughput Virtual Screening
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava, ...
    2023

  • A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
    KK Kaushik, R Mazumder, A Debnath, M Patel
    Letters in Drug Design & Discovery 20 (3), 264-278 2023

  • High-throughput virtual screening of novel CHK1 inhibitors.
    A Debnath, H Chaudhary, S Roy, S Srivastava
    Onkologia i Radioterapia 17 (1) 2023

  • Discovery of Novel Cathepsin D Inhibitors by High-Throughput Virtual Screening
    A Debnath, H Chaudhary, R Kumar, A Shokeen, R Khurana
    neurodegenerative diseases 9, 10 2023

  • In-Silico Investigation Based Plant Secondary Metabolites as Promising Immunostimulants against Covid-19
    S Das, A Debnath, MK Sharangi, S Das
    Suranaree Journal of Science and Technology 2022

  • A Brief Description of COVID-19 Pulmonary Viral Infection and Repurposing of Drugs for Its Treatment
    M Patel, R Mazumder, KK Kaushik, A Debnath, R Mishra, S Pal
    PATEL M, MAZUMDER R, KAUSHIK KK, DEBNATH A, MISHRA R, PAL S. A BRIEF 2022

  • Kidney targeting approaches In The Drug Delivery arena
    Singh S, Mazumder R, Debnath A, Dutta A
    NeuroQuantology 20 (8), 3424-3444 2022

  • A brief description of COVID-19 pulmonary viral infection and repurposing of drugs for its treatment

    International Journal of Applied Pharmaceutics 14 (5) 2022

  • In-silico and in-vivo evaluation of comparative enhanced neurogenic performance by energy drinks

    International Journal of Health Sciences 6 (S6), 5439–5454 2022

  • PD 1: A Trending Target in Anti-cancer Research
    S Rani, R Mazumder, N Sharma, R Mishra, A Debnath, SD Paul
    2022

  • Immune Checkpoint Inhibitors Targeting CTLA-4 in Cutaneous Malignancies: Recent Updates
    S Singh, R Mazumder, S Padhi, S Rani, A Debnath, R Mishra
    International Journal of Drug Delivery Technology 12 (1), 446-453 2022

  • In silico identification of Potential drug compound against N-Terminal Domain of the Androgen Receptor by Virtual screening, Docking, ADME toxicity and MD Simulation for the

    Research & Innovation 2018

  • Development, optimization, evaluation of inhalable solid SEDDS to cure pulmonary arterial hypertension

    Journal of Genetic Syndromes & Gene Therapy 8 (3) 2017

  • Evaluation of Antidepressant-Like Activity of Eriobotrya japonica in the Immobilization induced Stressed Mice

    International Journal of Pharmaceutical Sciences Review and Research 47 (1 2017

  • In-silico and in-vivo evaluation of comparative enhanced neurogenic performance by energy drinks
    S Das, I Khan, A Debnath, R Singh, S Dhasmana


MOST CITED SCHOLAR PUBLICATIONS

  • In Silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (5), 961-978 2024
    Citations: 1

  • A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
    KK Kaushik, R Mazumder, A Debnath, M Patel
    Letters in Drug Design & Discovery 20 (3), 264-278 2023
    Citations: 1